A. Schmittel

发表

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood.

C. Scheibenbogen, U. Keilholz, A. Schmittel, 1997, Journal of immunological methods.

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.

T. Gauler, P. Martus, K. Caca, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Intracellular Cytokine Staining

E. Thiel, C. Scheibenbogen, U. Keilholz, 2005 .

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients

E. Thiel, C. Scheibenbogen, U. Keilholz, 2005, International journal of cancer.

Rational peptide-based tumour vaccine development and T cell monitoring.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2003, Seminars in cancer biology.

Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides

E. Thiel, B. Seliger, C. Scheibenbogen, 2002, International journal of cancer.

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2002, Blood.

Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

E. Thiel, C. Scheibenbogen, K. Hellstrand, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

C. Loddenkemper, H. Buhr, A. Schmittel, 2009, Investigational New Drugs.

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

E. Thiel, T. Westhoff, W. Gerlich, 2003, Blood.

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.

E. Thiel, M. Weller, P. Martus, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma

D. Schadendorf, E. Thiel, C. Scheibenbogen, 2000, Journal of immunotherapy.

Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides

D. Schadendorf, E. Thiel, C. Scheibenbogen, 2003, International journal of cancer.

Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma

E. Thiel, P. M. Deckert, G. Hütter, 2005, Cancer.

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2001, Journal of immunological methods.

Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma

E. Thiel, A. Stroux, U. Keilholz, 2011, Oncology.

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2001, Journal of immunological methods.

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

V. Budach, I. Tinhofer, U. Keilholz, 2009, Clinical Cancer Research.

Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3): Results of a Phase 1/2 Study

K. Rühle, R. Ewert, C. Peschel, 2009, Journal of immunotherapy.

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.

J. von Pawel, C. Eschbach, M. Reck, 2013, Lung cancer.

Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study.

E. Thiel, G. Hütter, U. Keilholz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.

N. Utku, U. Keilholz, A. Schmittel, 2017, European journal of cancer.

Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité.

E. Thiel, V. Budach, C. Loddenkemper, 2009, Anticancer research.

Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)

E. Thiel, G. Hütter, U. Keilholz, 2007, Hematological oncology.

Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.

S. Loges, C. Grohé, B. Schmidt, 2022, Lung cancer.

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

D. Schadendorf, M. Gore, A. Eggermont, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification of Tumor-Specific T Lymphocytes With the ELISPOT Assay

E. Thiel, C. Scheibenbogen, U. Keilholz, 2000, Journal of immunotherapy.

Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.

E. Thiel, C. Scheibenbogen, U. Keilholz, 1999, International journal of cancer.

Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment.

E. Thiel, F. Dimeo, D. Böning, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

P. Murawa, M. Gore, C. Bokemeyer, 2010, International journal of cancer.

Malignant melanoma--clinical development of peptide-based melanoma vaccines.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2006, Frontiers of radiation therapy and oncology.

Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial.

A. Eggermont, P. Romero, C. Scheibenbogen, 2000, Journal of immunological methods.

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy

W. Verbeek, F. Perri, G. Ossenkoppele, 2011, Bone Marrow Transplantation.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

M. Beckmann, S. Marnitz, T. Fehm, 2022, Geburtshilfe und Frauenheilkunde.

CD 8 T-cell responses to Wilms tumor gene product WT 1 and proteinase 3 in patients with acute myeloid leukemia

E. Thiel, C. Scheibenbogen, U. Keilholz, 2002 .

Remission of extensive intrahepatic metastasis by C‐arm computed tomography guided chemoembolization in uveal melanoma

F. Wacker, C. Sunderkötter, A. Schmittel, 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[Prevention, diagnosis, therapy, and follow-up of lung cancer].

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

Localablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients.

N. Suttorp, C. Grohé, B. Schmidt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of tyrosinase‐reactive T cells by treatment with dacarbazine, cisplatin, interferon‐alpha ± interleukin‐2 in patients with metastatic melanoma

E. Thiel, C. Scheibenbogen, U. Keilholz, 1999, International journal of cancer.

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care

P. Galle, F. Staib, M. Indorf, 2017, Journal of Cancer Research and Clinical Oncology.

CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach

T. Zander, M. Egger, T. Seufferlein, 2018, Journal of Cancer Research and Clinical Oncology.

Second-line therapy for small-cell lung cancer

A. Schmittel, 2011, Expert review of anticancer therapy.

Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma.

E. Thiel, N. Bornfeld, C. Scheibenbogen, 2004, European journal of cancer.

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma.

E. Thiel, P. Kiewe, N. Bechrakis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

E. Thiel, H. Buhr, C. Scheibenbogen, 2000, Cancer research.

High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma

D. Schadendorf, E. Thiel, C. Scheibenbogen, 2000, International journal of cancer.

Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature

E. Thiel, S. Coupland, M. Foerster, 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.

E. Thiel, U. Keilholz, A. Schmittel, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.

E. Thiel, W. Knauf, A. Schmittel, 2004, The hematology journal : the official journal of the European Haematology Association.

Differences in T‐cell immunity toward tumor‐associated antigens in colorectal cancer and breast cancer patients

E. Thiel, C. Scheibenbogen, G. Schaller, 2003, International journal of cancer.

Application of the IFN-γ ELISPOT assay to quantify T cell responses against proteins

E. Thiel, S. Stevanović, C. Scheibenbogen, 2001 .

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

M. Beckmann, S. Marnitz, C. Hack, 2022, Geburtshilfe und Frauenheilkunde.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

S. Parsons, S. Al-Batran, P. Wimberger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Lipopolysaccharide Effectively Up‐Regulates B7‐1 (CD80) Expression and Costimulatory Function of Human Monocytes

C. Scheibenbogen, U. Keilholz, A. Schmittel, 1995, Scandinavian journal of immunology.

Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group.

L. Desjardins, S. Leyvraz, S. Piperno-Neumann, 2016, American journal of ophthalmology.

Catumaxomab: a bispecific trifunctional antibody.

M. Schmidt, M. Sebastian, A. Schmittel, 2009, Drugs of Today.

[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].

B. Witzenbichler, D. Westermann, H. Schultheiss, 2007, Der Internist.

Systemic Immune Tuning in Renal Cell Carcinoma: Favorable Prognostic Impact of TGF-&bgr;1 mRNA Expression in Peripheral Blood Mononuclear Cells

E. Thiel, K. Miller, U. Keilholz, 2011, Journal of immunotherapy.

The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum.

S. Marnitz, K. Kalache, C. Köhler, 2009, Fertility and sterility.

How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy.

S. Marnitz, C. Köhler, A. Schneider, 2015, American journal of obstetrics and gynecology.

Cisplatin Application in Pregnancy: First in vivo Analysis of 7 Patients

S. Marnitz, C. Köhler, A. Schneider, 2010, Oncology.

rituximab therapy Fatal hepatitis B virus reactivation by an escape mutant following

E. Thiel, T. Westhoff, W. Gerlich, 2011 .

Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.

N. Suttorp, C. Grohé, C. Furth, 2018, Lung cancer.

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

E. Thiel, B. Passlick, R. Buhl, 2007, Cancer Immunology, Immunotherapy.

A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma

E. Thiel, G. Hütter, U. Keilholz, 2007, Leukemia & lymphoma.

Controversies in the treatment of advanced stages of small cell lung cancer.

A. Schmittel, 2010, Frontiers of radiation therapy and oncology.

Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer?

U. Keilholz, A. Schmittel, 2009, Nature Clinical Practice Oncology.

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

E. Thiel, P. Martus, M. Sebastian, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.

E. Thiel, U. Keilholz, A. Schmittel, 2011, Anticancer research.

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

M. Reck, M. Sebastian, A. Schmittel, 2014, European Respiratory Review.

Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma

E. Thiel, N. Bornfeld, D. Strumberg, 2005, Melanoma research.

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

E. Thiel, K. Miller, U. Keilholz, 2011, European journal of cancer.

Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome

E. Thiel, F. Wacker, U. Keilholz, 2010, Melanoma research.

Addressing concerns about cisplatin application during pregnancy

S. Marnitz, C. Köhler, A. Schneider, 2011, Journal of perinatal medicine.

Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

E. Thiel, A. Eggermont, C. Scheibenbogen, 2004, Clinical Cancer Research.

A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy

T. Blum, W. Ludwig, T. Bauer, 2017, Case reports in oncological medicine.

A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma

E. Thiel, U. Keilholz, A. Schmittel, 2004, Melanoma research.

Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma

E. Thiel, C. Scheibenbogen, A. Stroux, 2007, Clinical Cancer Research.

Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins.

E. Thiel, S. Stevanović, C. Scheibenbogen, 2001, Journal of immunological methods.

Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2003, European journal of cancer.

P-974 Treatment of non-small cell lung cancer (NSCLC) patients withthe trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study

B. Passlick, F. Kanniess, M. Sebastian, 2005 .

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

E. Thiel, U. Keilholz, A. Schmittel, 2007, Lung cancer.

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.

C. Bokemeyer, R. Hofheinz, C. Peschel, 2008, Lung cancer.

Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients

Ulrich Keilholz, Zhian Liu, I. Tinhofer, 2010, Journal of Translational Medicine.

Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine

Ulrich Keilholz, Zhian Liu, Achim Schneider, 2010, Cancer biology & therapy.

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma

E. Thiel, U. Keilholz, M. Foerster, 2005, Melanoma research.

Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.

E. Thiel, U. Keilholz, A. Schmittel, 2005, Anticancer research.

Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy.

M. Johannsen, P. Hein, V. Grünwald, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

E. Thiel, U. Steiner, K. Miller, 2009, Oncology.

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.

E. Thiel, U. Keilholz, M. Foerster, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial

A. Rossi, C. Gridelli, A. Favaretto, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma.

E. Thiel, P. M. Deckert, G. Hütter, 2004, Journal of Clinical Oncology.

Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.

C. Loddenkemper, M. Zeitz, A. Schmittel, 2011, Pancreas.

A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.

E. Thiel, U. Keilholz, M. Foerster, 2004, European journal of cancer.

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.

E. Thiel, P. Martus, U. Keilholz, 2006, Annals of Oncology.

[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version].

H. Kauczor, I. Petersen, C. Rübe, 2011, Pneumologie.

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

E. Thiel, G. Hütter, U. Keilholz, 2004, Oncology Research and Treatment.